Vascular dysfunction in a transgenic model of Alzheimer's disease: Effects of CB1R and CB2R cannabinoid agonists

Frontiers in Neuroscience

Volumn 10, Issue SEP, 2016, Pages

  Navarro Dorado, Jorge ^a   Villalba, Nuria ^b   Prieto, Dolores ^b   Brera, Begoña ^c   Martín Moreno, Ana M ^c   Tejerina, Teresa ^a   de Ceballos, María L ^c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUTO CAJAL   (Spain)

Author keywords

Alzheimer's disease; Cannabinoid receptors; Collagen IV; Tg APP; Vascular dysfunction; amyloid

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; COLLAGEN TYPE 4; PHENYLEPHRINE;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTIC RING (SLICE); ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSGENIC MOUSE; VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION; VERY ELDERLY; WILD TYPE MOUSE;

EID: 84992166025     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2016.00422     Document Type: Article

References (57)

1. Arendash, G. W., Su, G. C., Crawford, F. C., Bjugstad, K. B., and Mullan, M. (1999). Intravascular beta-amyloid infusion increases blood pressure: implications for a vasoactive role of beta-amyloid in the pathogenesis of Alzheimer's disease. Neurosci. Lett. 268, 17-20.
2. Arévalo-Martín, A., García-Ovejero, D., Gómez, O., Rubio-Araiz, A., Navarro-Galve, B., Guaza, C., et al. (2008). CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br. J. Pharmacol. 153, 216-225. doi: 10.1038/sj.bjp.0707466
3. Ashton, J. C., Appleton, I., Darlington, C. L., and Smith, P. F. (2004). Immunohistochemical localization of cerebrovascular cannabinoid CB1 receptor protein. J. Cardiovasc. Pharmacol. 44, 517-519. doi: 10.1097/00005344-200411000-00001
4. Aso, E., and Ferrer, I. (2014). Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front. Pharmacol. 5:37. doi: 10.3389/fphar.2014.00037
5. Atwood, B. K., and Mackie, K. (2010). CB2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 160, 467-479. doi: 10.1111/j.1476-5381.2010.00729.x
6. Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Huffman, J. W., et al. (2000). Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404, 84-87. doi: 10.1038/35003583
7. Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., et al. (1999). Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65, 664-670.
8. Carnevale, D., Mascio, G., D'Andrea, I., Fardella, V., Bell, R. D., Branchi, I., et al. (2012). Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 60, 188-197. doi: 10.1161/HYPERTENSIONAHA.112.195511
9. Carnevale, D., Perrotta, M., Lembo, G., and Trimarco, B. (2016). Pathophysiological links among hypertension and Alzheimer's disease. High Blood Press. Cardiovasc. Prev. 23, 3-7. doi: 10.1007/s40292-015-0108-1
10. Cécyre, B., Thomas, S., Ptito, M., Casanova, C., and Bouchard, J. F. (2014). Evaluation of the specificity of antibodies raised against cannabinoid receptor type 2 in the mouse retina. Naunyn Schmiedebergs Arch. Pharmacol. 387, 175-184. doi: 10.1007/s00210-013-0930-8
11. Cheng, Y., Dong, Z., and Liu, S. (2014). β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPAR? pathway. Pharmacology 94, 1-12. doi: 10.1159/000362689
12. Chiurchiù, V., Leuti, A., and Maccarrone, M. (2015). Cannabinoid signaling and neuroinflammatory diseases: a melting pot for the regulation of brain immune responses. J. Neuroimmune Pharmacol. 10, 268-280. doi: 10.1007/s11481-015-9584-2
13. Christie, R., Yamada, M., Moskowitz, M., and Hyman, B. (2001). Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am. J. Pathol. 158, 1065-1071. doi: 10.1016/S0002-9440(10)64053-9
14. Crawford, F., Suo, Z., Fang, C., and Mullan, M. (1998). Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp. Neurol. 150, 159-168.
15. de Bitencourt, R. M., Pamplona, F. A., and Takahashi, R. N. (2013). A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers. Neuropharmacology 64, 389-395. doi: 10.1016/j.neuropharm.2012.05.039
16. De March, Z., Zuccato, C., Giampà, C., Patassini, S., Bari, M., Gasperi, V., de Ceballos, M. L., et al. (2008). Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions. Neuroscience 152, 734-740. doi: 10.1016/j.neuroscience.2007.11.044
17. Di Marzo, V., and De Petrocellis, L. (2012). Why do cannabinoid receptors have more than one endogenous ligand? Philos. Trans. R. Soc. Lond. B. Biol. Sci. 367, 3216-3228. doi: 10.1098/rstb.2011.0382
18. Fernández-Ruiz, J., Moreno-Martet, M., Rodríguez-Cueto, C., Palomo-Garo, C., Gómez-Cañas, M., Valdeolivas, S., et al. (2011). Prospects for cannabinoid therapies in basal ganglia disorders. Brit. J. Pharmacol. 163, 1365-1378. doi: 10.1111/j.1476-5381.2011.01365.x
19. Gardiner, S. M., March, J. E., Kemp, P. A., and Bennett, T. (2001). Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats. Brit. J. Pharmacol. 133, 445-453. doi: 10.1038/sj.bjp.0704100
20. Glass, M., Dragunow, M., and Faull, R. L. (2000). The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505-519. doi: 10.1016/S0306-4522(00)00008-7
21. Gómez Del Pulgar, T., de Ceballos, M. L., Guzmán, M., and Velasco, G. (2002). Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 277, 36527-36533. doi: 10.1074/jbc.M205797200
22. Grammas, P. (2011). Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J. Neuroinflammation 8:26. doi: 10.1186/1742-2094-8-26
23. Hamel, E., Royea, J., Ongali, B., and Tong, X. K. (2016). Neurovascular and cognitive failure in Alzheimer's disease: benefits of cardiovascular therapy. Cell. Mol. Neurobiol. 36, 219-232. doi: 10.1007/s10571-015-0285-4
24. Hardy, J. (1996). New insights into the genetics of Alzheimer's disease. Ann. Med. 28, 255-258.
25. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. doi: 10.1126/science.1072994
26. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W., et al. (2002). International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 61-202. doi: 10.1124/pr.54.2.161
27. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., et al. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102. doi: 10.1126/science.274.5284.99
28. Huffman, J. W., Liddle, J., Yu, S., Aung, M. M., Aboot, M. E., Wiley, J. L., et al. (1999). 3-(1', 1'-Dimethylbutyl)-1-deoxy-delta-8-THC and related compounds: synthesis and selective ligands for the CB2 receptor. Bioorg. Med. Chem. Lett. 7, 2905-2914.
29. Iadecola, C. (2010). The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 120, 287-296. doi: 10.1007/s00401-010-0718-6
30. Iadecola, C., Zhang, F., Niwa, K., Eckman, C., Turner, S. K., Fischer, E., et al. (1999). SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2, 157-161.
31. Kalaria, R. N. (2002). Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc. Dis. 13(Suppl. 2), 48-52. doi: 10.1159/000049150
32. Leweke, F. M., Mueller, J. K., Lange, B., and Rohleder, C. (2016). Therapeutic potential of cannabinoids in psychosis. Biol. Psychiatry 79, 604-612. doi: 10.1016/j.biopsych.2015.11.018
33. Li, Y., and Kim, J. (2015). Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus. Neuroscience 311, 253-267. doi: 10.1016/j.neuroscience.2015.10.041
34. López-Miranda, V., Herradón, E., and Martín, M. I. (2008). Vasorelaxation caused by cannabinoids: mechanisms in different vascular beds. Curr. Vasc. Pharmacol. 6, 335-346. doi: 10.2174/157016108785909706
35. Mancardi, G. L., Perdelli, F., Rivan, C., Leonardi, A., and Bugiani, O. (1980). Thickening of the basement membrane of cortical capillaries in Alzheimer's disease. Acta Neuropathol. 49, 79-83.
36. Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530-534. doi: 10.1038/nature00839
37. Martín-Moreno, A. M., Brera, B., Spuch, C., Carro, E., García-García, L., Delgado, M., et al. (2012). Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation 9:8. doi: 10.1186/1742-2094-9-8
38. Miao, J., Xu, F., Davis, J., Otte-Höller, I., Verbeek, M. M., and Van Nostrand, W. E. (2005). Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am. J. Pathol. 167, 505-515. doi: 10.1016/S0002-9440(10)62993-8
39. Morris, A. W., Carare, R. O., Schreiber, S., and Hawkes, C. A. (2014). The cerebrovascular basement membrane: role in the clearance of β-amyloid and cerebral amyloid angiopathy. Front. Aging Neurosci. 6:251. doi: 10.3389/fnagi.2014.00251
40. O'Sullivan, S. E. (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol. 152, 576-582. doi: 10.1038/sj.bjp.0707423
41. O'Sullivan, S. E. (2016). An update on peroxisome proliferator-activated receptor (PPAR) activation by cannabinoids. Br. J. Pharmacol. 173, 1899-1910. doi: 10.1111/bph.13497
42. Paris, D., Patel, N., Delle Donne, A., Quadros, A., Smeed, R., and Mullan, M. (2004). Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci. Lett. 366, 80-85. doi: 10.1016/j.neulet.2004.05.017
43. Pertwee, R. G. (2012). Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 367, 3353-3363. doi: 10.1098/rstb.2011.0381
44. Ramírez, B. G., Blázquez, C., Gómez del Pulgar, T., Guzmán, M., and de Ceballos, M. L. (2005). Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25, 1904-1913. doi: 10.1523/JNEUROSCI.4540-04.2005
45. Randall, M. D., Kendall, D. A., and O'Sullivan, S. E. (2004). The complexities of the cardiovascular actions of cannabinoids. Br. J. Pharmacol. 142, 20-26. doi: 10.1016/j.neulet.2004.05.017
46. Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240-244.
47. Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.-M., Casellas, P., Congy, C., et al. (1998). SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644-650.
48. Smith, C. C., Stanyer, L., Betteridge, D. J., and Cooper, M. B. (2007). Native and oxidized low-density lipoproteins modulate the vasoactive actions of soluble beta-amyloid peptides in rat aorta. Clin. Sci. 113, 427-434. doi: 10.1042/CS20070082
49. Stanley, C., and O'Sullivan, S. E. (2014). Vascular targets for cannabinoids: animal and human studies. Br. J. Pharmacol. 171, 1361-1378. doi: 10.1111/bph.12560
50. Suo, Z., Humphrey, J., Kundtz, A., Sethi, F., Placzek, A., Crawford, F., et al. (1998). Soluble Alzheimers beta-amyloid constricts the cerebral vasculature in vivo. Neurosci. Lett. 257, 77-80.
51. Thomas, A. J., Morris, C. M., Ferrier, I. N., and Kalaria, R. N. (2000). Distribution of amyloid beta 42 in relation to the cerebral microvasculature in an elderly cohort with Alzheimer's disease. Ann. N. Y. Acad. Sci. 903, 83-88. doi: 10.1111/j.1749-6632.2000.tb06353.x
52. Thomas, T., Thomas, G., McLendon, C., Sutton, T., and Mullan, M. (1996). β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168-171.
53. Tong, X., and K., Nicolakakis, N., Kocharyan, A., Hamel, E. (2005). Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J. Neurosci. 25, 11165-11174. doi: 10.1523/JNEUROSCI.4031-05.2005
54. Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., and Walker, J. M. (1997). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393-411.
55. Tsou, K., Mackie, K., Sañudo-Peña, M. C., and Walker, J. M. (1999). Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing gabaergic interneurons in the rat hippocampal formation. Neuroscience 93, 969-975.
56. Varga, K., Lake, K. D., Huangfu, D., Guyenet, P. G., and Kunos, G. (1996). Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28, 682-686.
57. Wu, J., Bie, B., Yang, H., Xu, J. J., Brown, D. L., and Naguib, M. (2013). Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiol. Aging 34, 791-804. doi: 10.1016/j.neurobiolaging.2012.06.011